Nearly half of the children receiving intranasal midazolam for laceration repair in the emergency department (ED) exhibited extreme procedural anxiety. Younger age, reduced sociability, and extremity ...

Intranasal midazolam is an effective alternative to the oral version for children undergoing dental treatments, according to a new study. Researchers found that when dentists administered the drug ...

Proximagen announced promising data from the pivotal Phase 3 trial of USL261 (intranasal midazolam) for the rescue treatment of seizure clusters. The primary efficacy endpoint was treatment success, ...

AUSTIN, Texas — For acute seizure emergencies in children, intranasal midazolam is as safe and effective as intravenously or rectally administered diazepam, according to a systematic review of ...

Intranasal (IN) midazolam was equally effective and showed comparable safety for the treatment of acute pediatric seizure emergencies as compared to intravenous (IV) or rectal diazepam, according to ...

Objective: To evaluate the feasibility of a sedation protocol based on Lidocaine spray and Intranasal Midazolam (INM) administered by Mucosal Atomizer Device (MAD) in uncooperative children undergoing ...

MAPLE GROVE, Minn., July 18, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an ...

Intranasal dexmedetomidine (Precedex) outperformed midazolam as anti-anxiety premedication for children age 12 and younger undergoing tonsillectomy and/or adenoidectomy in a randomized trial. Children ...

Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...

UCB said today it has acquired rights to Proximagen’s New Drug Application (NDA)-bound antiepilepsy candidate Midazolam Nasal Spray (USL261) for up to $370 million. Midazolam is being developed as a ...

About NAYZILAM1NAYZILAM® (midazolam) nasal spray CIV is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, ...